Vanguard Group
DTIL icon

Vanguard Group’s Precision BioSciences DTIL Stock Holding History

Vanguard Group’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.77M Buy
906,782
+414,186
+84% +$2.35M ﹤0.01% 3360
2025
Q3 		$2.72M Buy
492,596
+87,242
+22% +$418K ﹤0.01% 3478
2025
Q2 		$1.7M Buy
405,354
+124,271
+44% +$613K ﹤0.01% 3587
2025
Q1 		$1.34M Buy
281,083
+2,861
+1% +$14.6K ﹤0.01% 3622
2024
Q4 		$1.06M Buy
278,222
+14,258
+5% +$104K ﹤0.01% 3746
2024
Q3 		$2.37M Buy
263,964
+4,252
+2% +$40.9K ﹤0.01% 3502
2024
Q2 		$2.53M Sell
259,712
-1,119
-0.4% -$13.2K ﹤0.01% 3485
2024
Q1 		$3.54M Buy
260,831
+102,338
+65% +$1.25M ﹤0.01% 3421
2023
Q4 		$1.74M Buy
158,493
+2,057
+1% +$22.2K ﹤0.01% 3652
2023
Q3 		$1.6M Sell
156,436
-810
-0.5% -$12.4K ﹤0.01% 3662
2023
Q2 		$2.48M Sell
157,246
-748
-0.5% -$17.1K ﹤0.01% 3587
2023
Q1 		$3.57M Buy
157,994
+12,215
+8% +$402K ﹤0.01% 3462
2022
Q4 		$5.2M Buy
145,779
+15,941
+12% +$630K ﹤0.01% 3288
2022
Q3 		$5.06M Buy
129,838
+14,168
+12% +$673K ﹤0.01% 3321
2022
Q2 		$5.55M Sell
115,670
-4,379
-4% -$257K ﹤0.01% 3327
2022
Q1 		$11.1M Buy
120,049
+11,906
+11% +$1.62M ﹤0.01% 3094
2021
Q4 		$24M Buy
108,143
+5,069
+5% +$1.42M ﹤0.01% 2741
2021
Q3 		$35.7M Buy
103,074
+10,005
+11% +$3.39M ﹤0.01% 2545
2021
Q2 		$35M Buy
93,069
+15,968
+21% +$4.8M ﹤0.01% 2557
2021
Q1 		$23.9M Sell
77,101
-4,182
-5% -$1.46M ﹤0.01% 2689
2020
Q4 		$20.3M Buy
81,283
+11,100
+16% +$2.72M ﹤0.01% 2623
2020
Q3 		$13M Buy
70,183
+15,342
+28% +$3.05M ﹤0.01% 2659
2020
Q2 		$13.7M Buy
54,841
+8,386
+18% +$1.84M ﹤0.01% 2612
2020
Q1 		$8.4M Buy
46,455
+12,592
+37% +$3.3M ﹤0.01% 2698
2019
Q4 		$14.1M Buy
33,863
+17,177
+103% +$5.4M ﹤0.01% 2693
2019
Q3 		$4.2M Buy
16,686
+2,452
+17% +$798K ﹤0.01% 3199
2019
Q2 		$5.66M Buy
14,234
+11,734
+469% +$4.72M ﹤0.01% 3125
2019
Q1 		$1.35M Buy
+2,500
New +$1.33M ﹤0.01% 3549

Other funds holding DTIL

EAM
Empery Asset Management New York $83M AUM
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group's DTIL Position: Q4 2025 in Review

Vanguard Group increased its Precision BioSciences (DTIL) stake by 84% in Q4 2025, buying an estimated $2.35M and bringing the position to 906,782 shares worth $3.77M. The position accounts for ﹤0.01% of the portfolio, ranked #3360.

Vanguard Group first reported a position in DTIL in Q1 2019 and has held it in 28 quarters since. The position peaked at $35.7M in Q3 2021. 69 funds tracked by Wall St. Rank hold DTIL as of Q4 2025.

  • Vanguard Group held 906,782 shares of Precision BioSciences worth $3.77M as of Q4 2025.
  • Vanguard Group bought 414,186 Precision BioSciences shares in Q4 2025, an estimated $2.35M.
  • Precision BioSciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3360 holding.
  • Vanguard Group first reported a position in Precision BioSciences in Q1 2019 and has held it in 28 quarters since.
  • Vanguard Group's Precision BioSciences position peaked at $35.7M in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.